BrainsWay (BWAY) Competitors $9.83 +0.16 (+1.65%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BWAY vs. XAIR, DCTH, APEN, KIDS, AXGN, SIBN, TMCI, CATX, TCMD, and ZIMVShould you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Beyond Air (XAIR), Delcath Systems (DCTH), Apollo Endosurgery (APEN), OrthoPediatrics (KIDS), AxoGen (AXGN), SI-BONE (SIBN), Treace Medical Concepts (TMCI), Perspective Therapeutics (CATX), Tactile Systems Technology (TCMD), and ZimVie (ZIMV). These companies are all part of the "medical" sector. BrainsWay vs. Beyond Air Delcath Systems Apollo Endosurgery OrthoPediatrics AxoGen SI-BONE Treace Medical Concepts Perspective Therapeutics Tactile Systems Technology ZimVie Beyond Air (NASDAQ:XAIR) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations. Does the MarketBeat Community favor XAIR or BWAY? BrainsWay received 20 more outperform votes than Beyond Air when rated by MarketBeat users. However, 69.57% of users gave Beyond Air an outperform vote while only 66.67% of users gave BrainsWay an outperform vote. CompanyUnderperformOutperformBeyond AirOutperform Votes4869.57% Underperform Votes2130.43% BrainsWayOutperform Votes6866.67% Underperform Votes3433.33% Do analysts rate XAIR or BWAY? Beyond Air currently has a consensus target price of $3.67, indicating a potential upside of 645.86%. BrainsWay has a consensus target price of $13.17, indicating a potential upside of 33.94%. Given Beyond Air's higher probable upside, analysts clearly believe Beyond Air is more favorable than BrainsWay.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beyond Air 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00BrainsWay 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, XAIR or BWAY? Beyond Air has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Which has stronger earnings and valuation, XAIR or BWAY? BrainsWay has higher revenue and earnings than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeyond Air$1.16M30.59-$60.24M-$1.41-0.35BrainsWay$31.78M5.16-$4.20M$0.1098.31 Is XAIR or BWAY more profitable? BrainsWay has a net margin of 3.88% compared to Beyond Air's net margin of -2,369.17%. BrainsWay's return on equity of 3.52% beat Beyond Air's return on equity.Company Net Margins Return on Equity Return on Assets Beyond Air-2,369.17% -227.29% -106.51% BrainsWay 3.88%3.52%2.26% Does the media refer more to XAIR or BWAY? In the previous week, BrainsWay had 8 more articles in the media than Beyond Air. MarketBeat recorded 15 mentions for BrainsWay and 7 mentions for Beyond Air. BrainsWay's average media sentiment score of 0.89 beat Beyond Air's score of 0.55 indicating that BrainsWay is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beyond Air 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BrainsWay 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of XAIR or BWAY? 31.5% of Beyond Air shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 20.1% of Beyond Air shares are owned by insiders. Comparatively, 19.0% of BrainsWay shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryBrainsWay beats Beyond Air on 11 of the 17 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get BrainsWay News Delivered to You Automatically Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BWAY vs. The Competition Export to ExcelMetricBrainsWaySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.96M$4.42B$5.06B$8.82BDividend YieldN/A41.17%5.17%4.07%P/E Ratio98.3124.81125.9917.81Price / Sales5.1647.011,180.3874.38Price / CashN/A51.8733.8232.53Price / Book3.934.974.684.68Net Income-$4.20M$13.76M$119.54M$226.08M7 Day Performance8.74%-3.09%-2.45%-2.04%1 Month Performance-2.29%0.22%-4.06%0.06%1 Year Performance103.94%42.64%29.86%24.60% BrainsWay Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BWAYBrainsWay3.9884 of 5 stars$9.83+1.7%$13.17+33.9%+103.9%$161.28M$31.78M98.31120Gap UpXAIRBeyond Air4.5392 of 5 stars$0.49-5.8%$3.67+645.9%-69.1%$37.87M$1.16M0.0070Gap DownDCTHDelcath Systems3.5248 of 5 stars$9.63-2.8%$21.50+123.3%+256.7%$316.86M$2.07M0.0076APENApollo EndosurgeryN/AN/AN/AN/A$579.72M$76.86M-9.80202KIDSOrthoPediatrics4.0997 of 5 stars$25.50+4.9%$40.00+56.9%-19.9%$588.93M$148.73M-20.73200AXGNAxoGen2.7099 of 5 stars$12.90+1.2%$15.00+16.3%+113.2%$561.10M$159.01M0.00426SIBNSI-BONE4.3736 of 5 stars$12.15-1.4%$23.00+89.3%-32.6%$516.68M$138.89M0.00350Analyst ForecastInsider TradeAnalyst RevisionTMCITreace Medical Concepts1.0224 of 5 stars$7.98+2.8%$7.40-7.3%-7.1%$483.42M$187.12M0.00250CATXPerspective Therapeutics2.7597 of 5 stars$6.16-9.1%$21.57+250.2%N/A$458.24M$1.43M0.00116Analyst RevisionTCMDTactile Systems Technology3.7846 of 5 stars$15.56-1.3%$23.00+47.8%+23.1%$378.43M$274.42M23.94980ZIMVZimVie2.5824 of 5 stars$13.49+2.4%$18.33+35.9%+49.2%$363.48M$457.43M0.002,600 Related Companies and Tools Related Companies XAIR Alternatives DCTH Alternatives APEN Alternatives KIDS Alternatives AXGN Alternatives SIBN Alternatives TMCI Alternatives CATX Alternatives TCMD Alternatives ZIMV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BWAY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BrainsWay Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BrainsWay With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.